Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BEVLiN: Avastin + Low-dose Interferon in mRCC
NCT00796757Phase 2Completed
- Sponsor
- Roche
- Start
- Dec 2008
- Primary completion
- Feb 2012
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 2 trial of bevacizumab in renal cell carcinoma (RCC), sponsored by Roche. Started Dec 2008; status: completed.
02
Drugs
bevacizumab
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT00796757.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00796757.